
Sign up to save your podcasts
Or


The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content:
By JAMA Network4.6
162162 ratings
The utility of prostate-specific antigen (PSA) screening for prostate cancer detection is impacted by detection of cancers with low risk of mortality. Editorialist Jeffrey J. Tosoian, MD, MPH, discusses a pragmatic approach to prostate cancer screening with JAMA Deputy Editor Mary L. (Nora) Disis, MD. Related Content:

38,216 Listeners

43,608 Listeners

27,046 Listeners

135 Listeners

319 Listeners

543 Listeners

700 Listeners

505 Listeners

6,464 Listeners

304 Listeners

269 Listeners

3,364 Listeners

22 Listeners

13 Listeners

8 Listeners

7 Listeners

20 Listeners

30 Listeners

91 Listeners

516 Listeners

375 Listeners

17 Listeners

377 Listeners